Lyfebulb, the company co-founded by <strong>Dr. Karin Hehenberger PhD</strong>, with <strong>Dr. Steve Squinto</strong>, Venture partner Orbimed and <strong>Riccardo Braglia</strong>, CEO Helsinn, is about to launch an early-stage Autoimmune Disease / Diabetes Innovation Venture Fund. &nbsp;The Scientific Advisory Board is chaired by <strong>Robert Langer PhD</strong>, David H. Koch Institue, MIT.<br /> <br /> Focused on breakthrough opportunities in autoimmune, insulin-dependent diabetes and other associated autoimmune diseases. Our goals are to deliver a superior return on investment.

XYZ Ventures is seeking to raise $70 million for its maiden fund, according to an SEC filing. The newly formed firm was launched by Ross Fubini, a former venture partner at Canaan Partners.

UK publisher and social enterprise group Big Issue will seek family office investors to help it reach its £250 million (€287 million) target for an ambitious new social investment fund...